ATC Group: L01FD04 Trastuzumab deruxtecan

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of L01FD04 in the ATC hierarchy

Level Code Title
1 L Antineoplastic and immunomodulating agents
2 L01 Antineoplastic agents
3 L01F Monoclonal antibodies and antibody drug conjugates
4 L01FD HER2 (Human Epidermal Growth Factor Receptor 2) inhibitors
5 L01FD04 Trastuzumab deruxtecan

Active ingredients in L01FD04

Active Ingredient Description
Trastuzumab deruxtecan

Trastuzumab deruxtecan is a HER2-targeted antibody-drug conjugate. The antibody is a humanised anti-HER2 IgG1 attached to deruxtecan, a topoisomerase I inhibitor (DXd) bound by a tetrapeptide-based cleavable linker.

Related product monographs

Title Information Source Document Type  
ENHERTU Powder for concentrate for solution for infusion European Medicines Agency (EU) MPI, EU: SmPC
ENHERTU Powder for solution for injection FDA, National Drug Code (US) MPI, US: SPL/PLR

Medicines in this ATC group

United States (US)

Austria (AT)

Estonia (EE)

Finland (FI)

France (FR)

Ireland (IE)

Israel (IL)

Japan (JP)

Lithuania (LT)

Poland (PL)

Romania (RO)

United Kingdom (UK)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.